Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antiviral agents for treatment of flaviviridae infections

A kind of technology of medicinal salts and compounds, applied in the field of antiviral agents for treating Flaviviridae virus infection

Inactive Publication Date: 2004-09-08
PHARMASSET PHARMASSET
View PDF33 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No pharmacological data reported for the combination therapy above

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antiviral agents for treatment of flaviviridae infections
  • Antiviral agents for treatment of flaviviridae infections
  • Antiviral agents for treatment of flaviviridae infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0284] 5-(2,4; 3,5-di-O-benzylidene-D-hexitol (hexityl))-3-bromopyridine (13 and 14, R=H, R 5 =Br,W 6 = N, W 5 =W 7 =W 8 =CH).

[0285] To a solution of 3,5-dibromopyridine (1.45 g, 6.12 mmol) in anhydrous ether (50 mL) was slowly added (about 10 minutes) n-butyllithium (2.35 mL, 2.6M in hexane, 6.12mmol). After the addition was complete, the mixture was stirred for an additional 15 minutes. The mixture was then cooled to -78°C and a solution of 2,4;3,5-di-O-benzylidene-D-aldehyde-ribose (12,500 mg, 1.53 mmol) in tetrahydrofuran (5 mL) was added dropwise, and The reaction mixture was warmed to room temperature. Water (50 mL) was added to the reaction mixture. The organic layer was separated, washed with brine (30 mL×3), dried over sodium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel (20 g) using first dichloromethane and then 10% diethyl ether in dichloromethane as eluent to give a pale yellow product which crystallized in ethanol (...

Embodiment 2

[0330] 5-(2,4; 3,5-Di-O-benzylidene-D-hexitolyl)nicotinic acid methyl ester (13 and 14, R=H, R 5 =CO 2 CH 3 , W 6 = N, W 5 =W 7 =W 8 =CH)

[0331] Under argon atmosphere, at -78°C, to 5-(2,4; 3,5-di-O-benzylidene-D-hexitol)-3-bromopyridine (200mg, 0.43mmol) To a solution of mixed hexamethylphosphoric triamide (0.5 mL) and diethyl ether (5 mL) was added butyllithium (2 mL of 2.5M in n-hexane, 5 mmol). After the addition was complete, the mixture was stirred at -78°C for 15 minutes. A large excess of solid carbon dioxide was added and the mixture was allowed to warm to room temperature. 1N hydrochloric acid was added to acidify the mixture to pH 4, the organic layer was washed with brine (3 x 5 mL), dried over sodium sulfate. After removing sodium sulfate by filtration, the filtrate was cooled to 0°C and washed with a large excess of diazomethane in ether. Acetic acid was then added to destroy excess diazomethane. The mixture was concentrated in vacuo, and the residue...

Embodiment 3

[0344] Methyl 5-(2,4; 3,5-di-O-benzylidene-D-hexitolyl)nicotinamide (13 and 14, R=H, R 5 =CONH 2 , W 6 = N, W 5 =W 7 =W 8 =CH).

[0345] The allose / altrose form of 5-(2,4;3,5-di-O-benzylidene-D-hexitolyl)nicotinic acid methyl ester (220mg, 0.48mmol) was differentially The isomeric mixture was treated with saturated ammonia in methanol containing a catalytic amount of sodium hydride (ca. 2 mg), and the mixture was stirred at room temperature overnight. The solvent was removed in vacuo and the residue was chromatographed on a silica gel column with chloroform-methanol (95:5) as eluent. Methyl 5-(2,4;3,5-di-O-benzylidene-D-hexitolyl)nicotinamide was obtained as a mixture of allose-type / altrrose-type epimers ( 13 and 14, R = H, R 5 =CONH 2 , W 6 = N, W 5 =W 7 =W 8 =CH), 185mg (87%). 1 H NMR (Me 2 SO-d 6 ): δ3.5-4.3(5H, m, H-2′, 3′, 4′, 5′, 5″), 5.00(1H, m, H-1′), 5.64, 5.76, 5.77, 5.89( 2H, 4s, benzylidene-CH2 ), 8.29, 8.68, 8.95 (3H, 3m, pyridine).

[0346] Foll...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a composition and method for treating host including animals, especially human Flaviviridae (Hepavirus, Flavivirus, Pestivirus) virus infection, including BVDV and HCV infection, and abnormal cell proliferation, Administration of small molecules or pharmaceutically acceptable salts or prodrugs thereof is included.

Description

field of invention [0001] The present invention includes compounds and methods of treating Flaviviridae infections, such as bovine viral diarrhea virus ("BVDV"), West Nile virus (WNV) and hepatitis C virus (HCV). This application claims priority to US Provisional Application 60 / 256,066, filed December 15,2000. Part of the work in this study was supported by NIH-SBIR grant: 1 R43CA88578. Background of the invention [0002] Flaviviridae viruses are a group of positive single-stranded RNA viruses with a genome size of 9-15 kb. They are enveloped viruses of approximately 40-50 nm. A taxonomic overview of the Flaviviridae family is available from the International Committee for Taxonomy of Viruses. The Flaviviridae family includes three genera of viruses. [0003] 1. Flavivirus genus: This genus includes dengue virus family (Dengue virus, type 1 dengue virus, type 2 dengue virus, type 3 dengue virus, type 4 dengue virus), Japanese encephalitis virus (J...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/343A61K31/665A61K31/7076A61K45/00A61P31/12A61P35/00A61P37/04A61P43/00C07D307/88C07F9/655C07F9/6558C07H19/20C07H19/207C07H19/24
CPCC07F9/65517C07D307/88A61K31/7076C07H19/207C07H19/20A61P31/12A61P35/00A61P37/04A61P43/00
Inventor L·斯图伊维尔K·W·潘基维茨S·帕特森M·J·奥托渡边恭一
Owner PHARMASSET PHARMASSET
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com